You just read:

Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients

News provided by

Santaris Pharma A/S

Nov 05, 2011, 09:00 ET